OraSure Technologies Reports 7% Revenue Decline and Increased Operating Loss in Q1 2026

OraSure Technologies, Inc. reported a decrease in net revenues for the first quarter of 2026, totaling $27.9 million, down 7% from $29.9 million in the same period of 2025. The decline was primarily attributed to a significant drop in COVID-19 diagnostics sales, which fell 96% to $18,000, following the completion of a contract with the U.S. government and reduced demand for testing. Additionally, revenues from the company's hepatitis C (HCV) products decreased due to customer ordering patterns and funding constraints, although this was partially offset by increased sales of syphilis products. The gross profit margin improved to 42.3%, up from 41.1% year-over-year, driven by better operational efficiencies and an improved product mix.

The company's operating loss widened to $23.3 million for the first quarter of 2026, compared to a loss of $17.8 million in the prior year. This increase was largely due to higher research and development expenses, which surged 42% to $13.7 million, reflecting increased spending on clinical trials for new diagnostic devices. General and administrative expenses also rose by 3% to $14.6 million, influenced by higher professional service costs and severance charges related to workforce reductions. The company reported a net loss of $22.4 million, or $(0.32) per share, compared to a net loss of $16.0 million, or $(0.21) per share, in the previous year.

In terms of operational developments, OraSure's cash and cash equivalents decreased to $177.0 million as of March 31, 2026, down from $199.3 million at the end of 2025. The company’s working capital also fell to $196.7 million, reflecting changes in sales and inventory management. The company continues to maintain a strong cash position, with a significant portion held by its Canadian subsidiary, DNA Genotek Inc. The total liabilities increased to $65.8 million from $62.3 million, primarily due to higher accounts payable and accrued expenses.

Strategically, OraSure has been focusing on expanding its diagnostic portfolio, including the acquisition of BioMedomics in late 2025, which added the SickleSCAN® test to its offerings. The company is also pursuing new product launches, including a rapid molecular self-test for chlamydia and gonorrhea, currently under FDA review. The company has indicated that it will continue to invest in research and development to enhance its product offerings and market presence.

Looking ahead, OraSure Technologies anticipates ongoing challenges in the diagnostic market, particularly with the decline in COVID-19 related revenues. However, the company remains committed to its strategic initiatives, including the development of new diagnostic tests and the expansion of its sample management solutions. Management has expressed confidence in the long-term growth potential of its product lines and is focused on improving operational efficiencies to enhance profitability.